Transformative Therapeutics

NGM Bio is a clinical-stage biopharmaceutical company committed to developing first-in-class biologic therapeutics, with an initial focus on cardio-metabolic disease, liver disease and immuno-oncology. Our in-depth biology-based approach to drug discovery is designed to identify therapeutics that address the fundamental mechanisms underlying disease states. We are seeking to develop products that significantly improve upon existing treatments. Our goal is to generate transformative therapeutics that will profoundly improve patients’ lives.

NASH2, PSC1
Phase 2
     
Obesity, Diabetes, NASH2
Phase 1b
     
Obesity, Diabetes, NASH2
In Development
     
Obesity, Diabetes, NASH2
In Development
     
Anorexia/Cachexia in Cancer
Phase 1
     
Diabetes
Preclinical
     
AMD
Preclinical
     
Research Stage
Immuno-Oncology, Cardio-Metabolic, Liver and Retinal Disease
Discovery
     
Drug Candidate
Indication
Status

1 primary sclerosing cholangitis
2 non-alcoholic steatohepatitis